Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Administration of the same Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) in major depressive disorder (MDD) and in generalized anxiety disorder (GAD) before and after treatment allowed us to compare quality of life enjoyment and satisfaction in these two disorders and to compare outcome based on symptoms versus functioning. Q-LES-Q and symptom-specific Montgomery–Åsberg Depression Rating Scale (MADRS) and Hamilton Anxiety Scale (HAMA) data from eight randomized, 8-week, double-blind, placebo-controlled clinical trials with escitalopram were used. MDD (n=1140) or GAD (n=1045) patients report a substantial degree of quality of life enjoyment and satisfaction impairment (baseline scores 64% and 76% of community norm, respectively). Treatment resulted in statistically and clinically significant improvement in quality of life enjoyment and satisfaction. The improvement was greater in patients treated with escitalopram than with placebo. In MDD, the majority of remitters (MADRS≤12) reached ‘normal’ quality of life enjoyment and satisfaction levels, whereas in GAD, 67% of remitters (HAMA≤7) reached ‘normal’ quality of life, enjoyment, and satisfaction. A strong correlation between the symptom-specific scales and the Q-LES-Q was observed. These analyses suggest that remission with scores of 6 on the MADRS and 5 on the HAMA correspond with a quality of life enjoyment and satisfaction found in community comparison patients (Q-LES-Q score of 58±10%). Treatment with escitalopram results in a significant improvement of quality of life enjoyment and satisfaction in patients with MDD or GAD. Both response and remission in patients with GAD and remission in patients with MDD are correlated with a ‘normal’ quality of life enjoyment and satisfaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quality of Life in Individuals With Anxiety Disorders
Mendlowicz, M. V., & Stein, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.669 · Cited by 955 · cited 4×
“The latter ones have the advantage of permitting comparisons across conditions and populations (which can be important in the prioritization of budgets for health care), but it has been suggested that they can have the disadvantage of being less sensitive to change in specific conditions (Mendlowicz and Stein, 2000).”
BackgroundInfluentialQuality-of-Life Impairment in Depressive and Anxiety Disorders
Rapaport, M. H., Clary, C., Fayyad, R., & Endicott, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1171 · Cited by 914 · cited 7×
“‘Normal’ quality of life enjoyment and satisfaction scores are defined as scores within 10% of the community norm, reported as a Q-LES-Q score of 58 (Rapaport et al., 2005).”
BackgroundInfluentialHow Should Remission From Depression Be Defined? The Depressed Patient’s Perspective
Zimmerman, M., McGlinchey, J. B., Posternak, M. A., Friedman, M., Attiullah, N., & Boerescu, D. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.148 · Cited by 431 · cited 7×
“Unauthorized reproduction of this article is prohibited. such as optimism and self-confidence; a return to one’s usual, normal self; and a return to usual level of functioning (Zimmerman et al., 2006).”
BackgroundInfluentialQuality of life assessments in major depressive disorder: a review of the literature
Papakostas, G. I., Petersen, T., Mahal, Y., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2004) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2003.07.004 · Cited by 331
Public attitude towards psychiatric treatment
Angermeyer, M. C., & Matschinger, H. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb09868.x · Cited by 228
Leucht, S., & Engel, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300873 · Cited by 154 · cited 2×
“For the correlation analysis, MADRS and HAMA total scores were equated to Q-LES-Q using the method of equipercentile linking (Leucht and Engel, 2006; Leucht et al., 2005, 2006) by using all postbaseline data for each five-point cut on the Q-LES-Q and finding the corresponding value on the…”
MethodExecutive Dysfunction, Heart Disease Burden, and Remission of Geriatric Depression
Alexopoulos, G. S., Kiosses, D. N., Murphy, C., & Heo, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300557 · Cited by 117 · cited 2×
“…65 30.5 (4.1) 29.8 Kasper et al. (2005) Escitalopram 10–20 143 38 (12) 56 30.4 (4.0) 49.0 Flexible dose in MDD 8 weeks Placebo 132 41 (12) 57 30.7 (4.8) 42.4 Alexopoulos et al. (2004) Escitalopram 10–20 131 40 (11) 49 30.4 (4.4) 59.5 Sertraline 50–100 135 40 (11) 61 30.1 (4.6) 62.2 aZ50%…”
BackgroundInfluential
Cited by
Effect of treatments for depression on quality of life: a meta-analysis
Hofmann, S. G., Curtiss, J., Carpenter, J. K., & Kind, S. (2017) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2017.1304445 · Cited by 189
Restoring function in major depressive disorder: A systematic review
Sheehan, D. V., Nakagome, K., Asami, Y., Pappadopulos, E. A., & Boucher, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.029 · Cited by 182
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
A randomized controlled pilot trial of vilazodone for adult separation anxiety disorder
Schneier, F. R., Moskow, D. M., Choo, T.-H., Galfalvy, H., Campeas, R., & Sanchez-Lacay, A. (2017) · Depression and Anxiety · doi:10.1002/da.22693 · Cited by 35
Beidas, R. S., Volpp, K. G., Buttenheim, A. N., Marcus, S. C., Olfson, M., Pellecchia, M., Stewart, R. E., Williams, N. J., Becker-Haimes, E. M., Candon, M., et al. (2019) · JMIR Research Protocols · doi:10.2196/12121 · Cited by 28
Metadata
- Authors
- Demyttenaere, K., Andersen, H. F., & Reines, E. H.
- Venue
- International Clinical Psychopharmacology
- Published
- 2008-09
- Volume
- 23
- Issue
- 5
- Pages
- 276-286
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2067727301
- Cited by
- 55
- References
- 7
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. https://app.cochat.ai/papers/10.1097/yic.0b013e328303ac5f
- The paper
- Demyttenaere, K., Andersen, H. F., & Reines, E. H. (2008). Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e328303ac5f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.